The Protective Effects of Acetyl L-Carnitine on Testis Gonadotoxicity Induced by Cisplatin in Rats

Neslihan Coşkun1, M. Tahir Hatipoğlu1, Candan Özoğul1, Cem Korkmaz2, Seda Nur Akyol1, Serap Cilaker Micilli3, Gülistan Sanem Ank1, Deniz Erdoğan1

1Department of Histology and Embriyology, Gazi University School of Medicine, Ankara, Turkey 2IVF Laboratories, Gülhane Military Medical Academy, Ankara, Turkey 3Department of Histology and Embriyology, Dokuz Eylul University School of Medicine, İzmir, Turkey

ABSTRACT

Background: Cisplatin, an effective antineoplastic agent, damages normal cells in a manner related to chemotherapy. Acetyl L-carnitine protects cells against mitochondrial and nuclear damage induced by chemotherapy.

Aims: Animal experiment

Study Design: The aim of this study was to examine the protective effects of acetyl L-carnitine on cisplatin-induced gonadotoxicity in testicular structures. Twenty-four male Wistar albino rats were divided into four Groups (n=6): Group 1 (control) was administered saline; Group 2 was administered acetyl L-carnitine; Group 3 was administered cisplatin; and Group 4 was pre-treated with acetyl L-carnitine before cisplatin administration.

Methods: After 72hr of treatment with cisplatin, the rats were sacrificed, and the testicular tissues were removed. Morphometric, histomorphologic and immunohistochemical analyses were conducted.

Results: At the end of the experiment, Group 3 was characterised by statistically significant weight loss, a degenerative appearance of the seminiferous tubules in the peripheral region, separation of spermatogenic cell series from the tubular wall, cellular debris in the lumen and central interstitial oedema. Sperm morphology appeared to be abnormal. Tubular diameter and wall thickness decreased, and the number of TUNEL- and active caspase-positive cells increased compared with the other Groups. The histological findings in Group 4 were better than those in Group 3.

Conclusion: It was concluded that the prophylactic use of acetyl L-carnitine protects against cisplatin-induced testicular tissue damage.

Key Words: Acetyl L-carnitine, cisplatin, gonadotoxicity, testis

Received: 19.07.2012  Accepted: 14.02.2013

Introduction

The use of antineoplastic agents in cancer treatments has toxic effects on all rapidly growing healthy cells, such as those of the gastrointestinal system, hematopoietic system and reproductive system cells, in addition to tumour tissues (1-3).

Cisplatin induces cytotoxicity in healthy tissues by contributing to the production of reactive oxygen species, inducing mitochondrial oxidative damage and apoptosis, inhibiting antioxidant enzymes and releasing free radicals. Gonadotoxicity is one of the most important dose-limiting side effects (4-7). It directly affects the spermatogonia, inhibiting spermatogenesis or impairing the cellular functions of Sertoli cells, which leads to permanent infertility (8-10). Therefore, it has become important to supplement with antioxidants to reduce the damage created by anti-tumoural drugs (11).

L-carnitine was previously identified as a powerful antioxidant and free radical scavenger (12, 13). The potent anti-apoptotic ability of acetyl L-carnitine to prevent oxidative stress-related mitochondrial damage and subsequent mitochondria-dependent apoptosis has been demonstrated in many cell types (14-17). The high concentration of acetyl L-carnitine that is present in testicular tissues leads to an increase in mitochondrial fatty acid oxidation, which is used to produce energy for sperm respiration and motility (18-20).

Material and Methods

Animals and Experimental Design

Twenty-four adult male Wistar albino rats weighing 200-250 g were obtained from the Laboratory Animal Breeding
and Experimental Research Centre of Gazi University (GUDAM). The animals were housed under standard laboratory conditions (12 hr light/dark cycle, 20±2°C, relative humidity 50±15%) for three days. Standard food pellets and tap water were available ad libitum. The experimental protocol was approved by the Ethical Committee of Gazi University.

The rats were divided into four Groups: Group 1 (n=6) (control) was given saline; Group 2 (n=6) was treated with acetyle L-carnitine; Group 3 (n=6) was treated with cisplatin; and Group 4 (n=6) was pre-treated with acetyle L-carnitine before cisplatin treatment. The actual experimental findings, however, were interpreted using only 23 rats because one rat from Group 3 died during the experimental process.

Acetyle L-carnitine (Sigma®, Germany, 200 mg/kg body weight, 600 mg dissolved in 3 mL of saline solution) was injected subcutaneously (s.c.) into the rats in Groups 2 and 4. Saline was simultaneously injected s.c. at the same dose in Groups 1 and 3. Cisplatin (Cisplatin-Ebewe® 13 mg/kg body weight, Liba, Istanbul, Turkey) was administered 30 min after acetyle L-carnitine/saline injection via intraperitoneal infusion for 1 hr only on the first day in Groups 3 and 4 (15, 16).

Rats were sacrificed 72 hr after cisplatin treatment (the fourth day) using anaesthesia with ketamine hydrochloride (40 mg/kg) (Ketalar, Eczacibasi, Istanbul, Turkey) and xylazine hydrochloride (5 mg/kg) (Rompun, Bayer, Istanbul, Turkey). After sacrificing, the testicular tissues of the rats were removed.

**Histological and Morphometric Investigations**

The testes were fixed in 10% neutral buffered formalin and embedded in paraffin and used for routine histological procedures were performed. Then, 4 µm sections were obtained from each paraffin block and stained with haematoxylin and eosin (H&E). Histological analysis was performed using a light microscope (Leica DM 4000, Germany). Seminiferous tubule diameter and wall thickness were measured using the same microscope and a computer-supported imaging system. Measurements of tubular walls were performed in 10 randomly selected areas in six cross-sections for each Group, and the results were compared.

**Testicular Sperm Extraction**

Left testicular tissues collected from each Group were placed in dishes containing fertilisation medium (G-IVF™ PLUS) for the testicular sperm extraction (TESE) method, and the tissues were divided into pieces using insulin injector tips. The fertilisation medium including the sperm was then transferred to gradient medium (1 mL of G-IVF™ PLUS medium and ISOLATE 9, 7 and 3 mL aliquots of the medium were used to prepare the 90, 70 and 30% gradients, respectively). These tubes were centrifuged at 1300 rpm for 10 min. Sperm that precipitated to the bottom were re-centrifuged twice at 1300 rpm in the fertilisation medium to remove the gradient medium. After rinsing, sperm that precipitated were spread onto a slide and stained by the KRUGER method, and their morphology was determined.

**TUNEL Assay**

The terminal deoxynucleotidyl transferase dUTP nick end-labelling (TUNEL) method was used to assess DNA fragmenta-

**Immunohistochemical Procedure**

The avidin-biotin peroxidase method was used for the immunohistochemical studies to investigate anti-caspase-3, -8 and -9 activities. Four micron-thick cross-sections prepared from testicular tissue blocks were incubated at 61°C. The tissues were deparaffinised by rinsing with sequential xylol and alcohol solutions, and distilled water was used to remove the alcohol from the dehydrated tissues. To expose receptor areas within the tissue that were blocked by formaldehyde, tissues were exposed to citrate buffer (pH 6.0) (Lab Vision, Fremont, USA) under a high temperature. Following the antigen retrieval procedure, the tissues were allowed to cool down at room temperature for 20 min and then rinsed with distilled water to remove the citrate. Tissues were rinsed with PBS three times for 3 min each, exposed to 3% hydrogen peroxide (Lab Vision, Fremont, USA) for 15 min to block endogenous peroxidase activity and subsequently rinsed with PBS. Ultra V block (Lab Vision, Thermo Scientific) was applied for 5 min to prevent non-specific binding. Following the blocking stage, sections were kept at room temperature for 45 min without being washed and exposed to anti-caspase-9 antibody (caspase-9 Ab-4), anti-cleaved caspase-3 antibody (caspase 3 (CPP32) Ab-4) and primer antibodies that were diluted 1:100. An anti-caspase-8 primer antibody was incubated overnight at +4°C. Procedures were resumed the next day. The tissues were rinsed with PBS following the primer antibody, and a secondary antibody (Lab Vision, Thermo Scientific) was applied for 10 min. The tissues were then rinsed with PBS, exposed to a streptavidin peroxidase enzyme (Lab Vision, Thermo Scientific) complex for 10 min and again rinsed with PBS. Lastly, DAB (Spring Bioscience) was added to the medium for approximately 5-10 min to ensure an immune reaction. Mayer’s haematoxylin was used as a background stain. The slides were then rinsed using serial alcohol solutions of diminishing concentrations. They were exposed to xylol for 20 min and were coated with entallan.
Cross-sections were evaluated under a light microscope (Leica DM 4000 Germany) using a computer-supported imaging system to take images with the Leica Q Vin 3 program.

**Statistical analyses**

All statistical analyses were performed using SPSS statistical software (SPSS for windows, version 11.0). All data were expressed as the mean±SD. The differences between rat weights measured at baseline and at the end of the experiment were statistically evaluated using the Wilcoxon signed rank test. Seminiferous tubule diameters and tubular wall thickness were measured in six cross-sections from each Group. TUNEL-positive and caspase-3-, -8- and -9-immunoreactive cells were counted out of 100 cells in 10 randomly selected areas on tubular walls in six cross-sections from each Group. Data obtained from the counts in binary Groups were evaluated using the Mann Whitney U test; p values less than 0.05 were accepted as statistically significant.

**Results**

**Statistical Assessment of the Body Weights**

Total average body weights of the rats were measured at baseline and upon completion of the experiment. The weights at baseline were 235.50±11.05 g in Group 1; 239.00±3.16 g in Group 2; 259.60±4.50 g in Group 3; and 257.33±5.31 g in Group 4. Weights at the end of the experiment were 239.66±10.94 g in Group 1; 226.16±4.70 g in Group 2; 214.20±9.09 g in Group 3; and 216.50±6.89 g in Group 4 (Figure 1). While the difference between the body weights at baseline and completion of the experiment were less significant in Group 1 (p=0.046), the loss in weight at the completion of the experiment was statistically significant in Groups 2 (p=0.027), 3 (p=0.041) and 4 (p=0.027) compared with baseline. It was observed that weight loss was significantly greater (p<0.05) in rats that experience cisplatin-induced gonadotoxicity compared with those from the other Groups.

**Evaluation of Tubular Diameter and Tubular Wall Thickness**

The mean seminiferous tubular diameters were 237.8±28.50 µm in Group 1; 236.1±29 µm in Group 2; 198.6±28.40 µm in Group 3; and 217.8±26.40 µm in Group 4. The mean values of tubular wall thicknesses were as follows: 94.2±16.6 µm in Group 1; 91.4±13.7 µm in Group 2; 68.2±21.20 µm in Group 3; 79.8±12.8 µm in Group 4 (Figure 2). While no significant differences were observed between Groups 1 and 2 (p=0.755) regarding tubular diameter (p>0.05), the tubular diameters in Group 3 were significantly lower compared with Groups 1 (p=0.000), 2 (p=0.000) and 4 (p=0.000). Tubular diameters in Group 4 were greater compared with Group 3 (p=0.000) and lower compared with Groups 1 (p=0.000) and 2 (p=0.000). Additionally, there were no significant differences between Group 1 and Group 2 in tubular wall thickness (p=0.310). The tubular wall thickness in Group 3 was significantly lower than in Groups 1 (p=0.000), 2 (p=0.000) and 4 (p=0.015). The tubular wall thickness in Group 4 was greater than in Group 3 (p=0.015) and lower than in Group 1 (p=0.000) and Group 2 (p=0.001).

**Histomorphologic Findings**

In the tissue cross-sections prepared from samples taken from Group 1, the histological characteristics of the testis were normal (Figure 3a). When testicular tissues from Group 2 were histomorphologically evaluated, they were found to be similar to Group 1 (Figure 3b). Degenerative alterations in the peripheral region of seminiferous tubules, separation of spermatogenic cell series from the seminiferous epithelium, cellular debris in the lumen and central interstitial oedema were observed in sections from Group 3 (Figures 3c-3e). The findings of Group 4 tissues were similar to those of Groups 1 and 2 (Figure 3f).

Normal sperm morphologies were observed in the TESE material obtained from Groups 1, 2 and 4 (Figures 4a, 4b, 4g and 4h). In contrast, Group 3 was characterized by numerous sperm with bent heads and mid-piece anomalies, looping mid-pieces, lasso-like morphologies and sperm with cytoplasmic droplets (Figures 4c-4f).

**TUNEL findings**

The number of TUNEL-positive and -negative cells was determined, and the mean values of TUNEL-positive cells were found. Group 1 had 8.84±1.56 cells; Group 2 had
9.4±2.17 cells; Group 3 had 20.10±4.47 cells; and Group 4 had 13.50±2.77 cells (Figure 5). TUNEL-positive cell numbers were significantly highest in Group 3 (p<0.05) compared with Groups 1 (p=0.000), 2 (p=0.000) and 4 (p=0.000). The mean number of cells displaying DNA fragmentation in Group 4 was higher compared with Groups 1 (p=0.000) and 2 (p=0.000) and lower compared with Group 3 (p=0.000). When compared with Groups 1 and 2, however, they were not statistically significant (p=0.360) (see Figure 6).

Immunohistochemical findings
The average number of cells expressing caspase-9 was 17.90±1.79 in Group 1; 24.79±1.91 in Group 2; 37.61±2.21 in Group 3; and 20.68±1.60 in Group 4 (Figure 5). TUNEL-positive cell numbers were significantly highest in Group 3 (p<0.05) compared with Groups 1 (p=0.000), 2 (p=0.000) and 4 (p=0.000). The mean number of cells displaying DNA fragmentation in Group 4 was higher compared with Groups 1 (p=0.000) and 2 (p=0.000) and lower compared with Group 3 (p=0.000). When compared with Groups 1 and 2, however, they were not statistically significant (p=0.360) (see Figure 6).

The average number of cells expressing caspase-9 was 17.90±1.79 in Group 1; 24.79±1.91 in Group 2; 37.61±2.21 in Group 3; and 20.68±1.60 in Group 4 (Figure 5). While caspase-9 activity was statistically significant (p<0.05) in all Groups, it was highest in Group 3 compared with Group 1, 2 or 4 (p=0.000). Group 4 was significantly different from Groups 1 (p=0.000) and 2 (p=0.000). The mean number of caspase-9-positive cells was, however, equivalent to Groups 1 and 2, but was lower compared to Group 3 (p=0.000) (see Figure 6).

The average amount of caspase-8-immunoreactivity in the seminiferous tubule epithelium was 5.2±0.63 in Group 1; 5.1±0.78 in Group 2; 13.3±19.1 in Group 3; and 8.4±9.84 in Group 4 (Figure 5). Caspase-8 activity was highest in Group 3, while the mean number of caspase-8-positive cells in Group 4 (p=0.000) was higher compared with Groups 1 (p=0.000) and 2 (p=0.000) and lower compared with Group 3 (p=0.021). When compared with Groups 1 and 2, however, these values were not statistically significant (p=0.343) (see Figure 6).

The mean number of cells that were immunoreactive for caspase-3 was 4.11±0.73 in Group 1; 5.5±1.07 in Group 2; 10.7±1.77 in Group 3; and 6.1±0.89 in Group 4 (Figure 5). Caspase-3 activity was highest in Group 3 compared with Groups 1, 2 or 4 (p=0.000). The mean number of caspase-3-positive cells in Group 4 was statistically significant compared with Groups 1 (p=0.000) and 2 (p=0.000). However, the mean number of caspase-3-positive cells was similar to Groups 1 and 2 but lower compared with Group 3 (p=0.000) (Figure 6).
Figure 5. The mean number of TUNEL and caspase-9-, -8- and -3-positive cells. (* mean number of TUNEL-positive and caspase-9-immunopositive cells were significantly higher in Group 3 compared with the other Groups, p<0.05)

Discussion

Cisplatin, which is an antineoplastic agent, was introduced for clinical use after being approved by the American Food and Drug Administration in 1978 (4). Cisplatin is frequently used to treat ovarian, testicular, lung and liver solid tumours. Due to the structural similarity between normal cells and tumour cells, chemotherapeutic drugs, such as cisplatin, cause damage to normal cells in a manner similar to that caused by chemotherapy. However, the powerful anti-tumoural activity of cisplatin also stops the growth and proliferation of cancer cells. Common adverse effects, such as gonadotoxicity, nephrotoxicity, ototoxicity and neurotoxicity, have been reported as dose-limiting adverse effects (5, 15, 16). After entering a tumour cell, cisplatin activates many signalling pathways to cause apoptosis, necrosis, oxidative stress, fibrogenesis, inflammation, hypoxia and mitochondrial damage, and it also induces cytotoxic effects in healthy cells (7, 10, 21-23). Moreover, Zhang et al. (9) demonstrated that apoptosis was induced in male germ cells in a dose-dependent fashion following cisplatin administration in Balb/c mice. These authors also observed that the maturity period for cells in the spermatogenic series decreased, that spermatogenesis was reduced and that fertility was affected.

Acetyl L-carnitine has been shown to protect cells against mitochondrial and free radical-related nuclear DNA damage and to improve mitochondrial functions by reducing stress-mediated DNA damage through reducing the production of oxidants and enhancing antioxidant status (13, 14-17). Many studies have demonstrated that free carnitine levels in the epididymis affect the number, motility and maturity of spermatozoa (18, 19). Topcu et al. (24) stated that administration of gamma radiation caused irregularities in and reduced the number of germ cells, as evidenced by morphological analyses, the pausing of spermatogenesis and vacuolisation in the germinal epithelium. In contrast, administration of L-carnitine alleviated the reduction in germ cell numbers and morphological damage in testicular tissues and exhibited protective effects against the damage caused by radiotherapy.

We examined the effects of cisplatin on testicular tissues and sperm structures using histomorphologic, morphometric, biochemical and apoptotic analyses. Our results suggest that cisplatin treatment induces central interstitial oedema, spermatogenic cells to part from the tubular walls and cellular debris to accumulate in the lumen of some tubules. When the sperm morphologies were examined with TESE, many sperm were observed with bent heads, mid-piece anomalies, looping mid-pieces, lasso-like shapes and cytoplasmic droplets (25). The histomorphologic findings in the acetyl L-carnitine+cisplatin pre-treatment Groups were similar to those observed in Groups 1 and 2.

Recently, Favareto et al. (26) assessed the effects of cisplatin treatment and the reversibility of these effects in Wistar albino male rats. After cisplatin treatment, the production of sperm and spermatogenic cell series were decreased, as were tubular diameter, intratesticular testosterone and fertility potential. Consistent with the literature, the morphometric evaluation of seminiferous tubule diameter and tubular wall thickness in the cisplatin treatment Group revealed that they were significantly smaller compared with Groups 1, 2 and 4. In addition, the acetyl L-carnitine+cisplatin pre-treatment Group had greater values compared with the cisplatin treatment Group.

Atessahin et al. (27) concluded that the toxic effects induced by cisplatin administration include a decrease in sperm concentrations, a reduction in sperm motility, an increase in abnormal sperm ratios, a thinning of the seminiferous epithelium, a decrease in the number of seminiferous tubules, an accumulation of germinal cellular debris, oedema in the interstitial area, an increase in lipid peroxidation and a decrease in glutathione peroxidase (GSH-Px) activity. The same authors concluded that following melatonin administration, the GSH-Px antioxidant defence system was enhanced and protective against reactive oxygen radicals, the number of abnormal sperm was reduced, sperm motility and epididymal sperm concentrations were increased and interstitial oedema was reduced. These results were similar to those obtained in our study.

Moreover, Lirdi et al. (28) reported that amifostin protected rats that were administered cisplatin by reducing the num-
ber of germinal cells with abnormal nuclear morphology (as evaluated by the TUNEL method) and the number of TUNEL-positive spermatogonia and primary spermatocytes. At the completion of cisplatin therapy, the number of TUNEL-positive seminiferous tubules and immotile sperm was increased compared with the control Group (26). This result was confirmed in our study, in which the increased number of TUNEL-positive cells in tubular walls of the cisplatin Group indicated that cisplatin induces apoptosis in the testicular germ cells. Moreover, acetyl L-carnitine+cisplatin pre-treatment prevented DNA fragmentation.

We also investigated the mechanisms of cisplatin-induced testicular apoptosis, which included an examination of apoptotic pathways induced by caspases-3, -8 and -9. We found that in the cisplatin Group, the average number of cells labelled for caspases-8 and -9 were significantly different compared with the other Groups. These findings suggest that cisplatin triggers apoptosis through caspases-8 and -9 and that pre-treatment prevents apoptosis via the extrinsic and intrinsic pathways. The significantly lower values of caspase-8 activity in the cisplatin Group compared with caspase-9 suggest that testicular apoptosis induced by cisplatin is primarily triggered by intrinsic factors through caspase-9. These results indicate that cisplatin administration initiates the apoptotic process by activating procaspase-3 and that apoptosis occurs via both the intrinsic and extrinsic paths. The intrinsic pathway, however, was more effective.

High rat mortality rates due to the toxic effects of cisplatin limited our study. Additionally, ultrastructural analyses of testicular tissues were limited due to budgetary reasons.

Studies related to protecting gonads for cancer patients undergoing chemotherapy are ongoing. Currently, sperm or testicular biopsy samples are frozen before chemotherapy treatments are given to male cancer patients. Our study utilized histomorphologic, morphometric and apoptotic parameters to demonstrate that cisplatin caused damage to testicular tissues and sperm morphology and that these damages were alleviated by pre-treating with acetyl L-carnitine. The results of this study indicated that the prophylactic use of acetyl L-carnitine can be recommended to protect testicular tissue in male patients after chemotherapy treatment.

**Ethics Committee Approval:** Ethics committee approval was received for this study from the ethical committee of Gazi University.

**Informed Consent:** N/A

**Peer-review:** Externally peer-reviewed.


**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** This study was supported by the Gazi University Scientific Research Project Unit, Ankara, Turkey.


28. Lirdi LC, Stumpf T, Sasso-Cerri E, Miraglia SM. Amifostin protective effect on cisplatin-treated rat testis. Anat Rec (Hoboken) 2008;291:797-808. [CrossRef]